Sponsor: ADC Therapeutics SA
Sponsor Study ID: ADCT-402-311
Study Title: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
CTO #: 103266
NCT Number: NCT04384484
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Non-Hodgkin's Lymphoma
Study Objectives: The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.